Ketamine Maintenance Infusion Protocols: Frequency and Duration Optimization

Introduction: The Maintenance Challenge in Ketamine Therapy

The rapid-acting antidepressant effect of ketamine -- while remarkable in its onset -- is characteristically transient following single infusion administration, with most patients experiencing symptomatic relapse within one to two weeks (Zarate et al., 2006). Ketamine maintenance infusion protocols have emerged as clinical strategies to sustain the initial therapeutic response through repeated dosing, yet optimal frequency, duration, and tapering approaches remain incompletely defined. The development of evidence-based maintenance protocols represents one of the most pressing clinical needs in the ketamine therapy landscape, as the practical utility of this intervention depends critically on the ability to deliver sustained benefit without cumulative safety risks (Phillips et al., 2019).

The challenge of maintenance treatment reflects a fundamental tension between efficacy and safety: more frequent dosing may better sustain antidepressant effects but increases exposure-related risks including cognitive effects, urological toxicity, and abuse potential. Conversely, infrequent dosing reduces exposure but may allow symptomatic relapse. Navigating this tension requires understanding the kinetics of therapeutic response and relapse, individual variability in treatment durability, and the biological mechanisms that govern the persistence of ketamine's synaptic effects.

Acute Phase: Induction Protocols

Standard Six-Infusion Induction

The most widely employed induction protocol consists of six intravenous ketamine infusions (0.5 mg/kg over 40 minutes) administered over two to three weeks, typically on a thrice-weekly (Monday-Wednesday-Friday) or twice-weekly schedule. This regimen was systematically evaluated by Shiroma and colleagues (2014) in an open-label trial of 14 treatment-resistant depression patients, reporting cumulative response rates of 92% and remission rates of 67% by the sixth infusion, published in Journal of Affective Disorders.

Phillips and colleagues (2019), in a landmark randomized controlled trial published in The American Journal of Psychiatry, compared thrice-weekly intravenous ketamine (0.5 mg/kg) with midazolam placebo over a four-week induction period (12 infusions total). The ketamine group demonstrated significantly greater antidepressant response (59% versus 29%) and remission (29% versus 6.5%) rates. Notably, a cumulative dose-response pattern was observed, with progressive improvement across the infusion series rather than plateau after the first few treatments -- supporting the rationale for multi-infusion induction courses.

Dose Titration During Induction

Some clinical protocols incorporate dose titration across the induction series, beginning at 0.5 mg/kg and adjusting upward (to 0.75-1.0 mg/kg) in subsequent sessions for incomplete responders or downward for patients experiencing intolerable side effects. The evidence supporting systematic dose titration is limited to case series and expert opinion, as no randomized trials have compared fixed-dose versus titrated induction protocols. Singh and colleagues (2016), in a dose-finding study of intravenous esketamine published in Biological Psychiatry, demonstrated dose-dependent antidepressant efficacy across 0.2 and 0.4 mg/kg doses, supporting the general principle that higher doses within the sub-anesthetic range may benefit some patients.

Maintenance Phase: Sustaining Response

Evidence for Repeated Dosing

The transition from induction to maintenance represents a critical clinical juncture. Murrough and colleagues (2013), published in Biological Psychiatry, followed 24 ketamine responders after a single infusion and documented median time to relapse of 18 days. aan het Rot and colleagues (2010) demonstrated that six infusions over two weeks produced a mean duration of response of approximately 19 days following the final infusion, published in Biological Psychiatry. These data establish that even multi-infusion induction courses do not produce indefinitely sustained responses, necessitating ongoing maintenance treatment for most patients.

Rasmussen and colleagues (2013) described one of the first published maintenance ketamine protocols, administering repeated infusions at individually tailored intervals ranging from weekly to monthly based on symptom recurrence. Over observation periods of up to 14 months, patients maintained antidepressant response with a mean inter-infusion interval of approximately three weeks. This pragmatic, symptom-guided approach has been widely adopted in clinical practice but lacks randomized controlled trial validation.

Frequency Optimization

Determining the optimal maintenance infusion frequency requires balancing efficacy against exposure burden. The available evidence, while limited, suggests several general principles:

• Weekly maintenance: Some patients require weekly infusions to maintain response, particularly during the early post-induction period. This frequency may be appropriate for the first one to two months following induction, with subsequent interval extension as tolerated.
• Biweekly (every two weeks): A common maintenance frequency that balances efficacy and practicality for many patients. Diamond and colleagues (2014) described successful maintenance at biweekly intervals in a case series of treatment-resistant depression patients.
• Monthly maintenance: Some patients can extend to monthly infusions while maintaining response, particularly those who demonstrated robust and durable response during induction. Singh and colleagues (2016) reported sustained efficacy with monthly esketamine maintenance in the phase II esketamine program.
• Symptom-guided intervals: Rather than fixed schedules, some protocols use symptom monitoring (patient-rated depression scales, clinician assessment) to trigger maintenance infusions when symptoms begin to recur. This approach minimizes total exposure but requires frequent monitoring and may result in periods of partial symptom return.

Tapering Strategies

Gradual extension of the inter-infusion interval -- tapering -- represents a practical approach to minimizing total ketamine exposure while maintaining therapeutic benefit. A typical tapering algorithm might progress from weekly to biweekly to monthly infusions over a three to six-month period, with interval extension contingent on sustained symptom control. The Spravato prescribing information endorses a similar approach for esketamine: twice-weekly for the first month, then weekly or every-two-weeks during subsequent months.

Daly and colleagues (2019), in the long-term esketamine maintenance trial published in JAMA Psychiatry, randomized stable esketamine responders to continued esketamine or placebo nasal spray, demonstrating significantly lower relapse rates with continued esketamine (26.7%) versus placebo (45.3%) over 16 weeks. This trial provides the strongest evidence to date that ongoing maintenance treatment prevents relapse, and that discontinuation carries substantial relapse risk.

Duration of Treatment

Defining Adequate Trial Duration

No consensus exists regarding the total duration of ketamine maintenance treatment. In clinical practice, treatment courses range from a few months (as a bridge to other interventions) to open-ended ongoing therapy. The absence of long-term efficacy data beyond one to two years limits evidence-based duration recommendations.

Several clinical scenarios inform treatment duration decisions:

• Bridge therapy: Ketamine used as a bridge during initiation or optimization of conventional antidepressant therapy, with planned discontinuation after the conventional agent reaches full therapeutic effect (typically 6-12 weeks).
• Augmentation therapy: Ongoing ketamine maintenance as augmentation of partially effective conventional treatment, with periodic reassessment of continued need.
• Standalone therapy: Ketamine as the primary antidepressant for patients who have failed multiple conventional agents, potentially requiring indefinite maintenance.

Discontinuation and Relapse Risk

The relapse risk following ketamine discontinuation is substantial and represents a major clinical consideration. In the Daly et al. (2019) esketamine study, nearly half of patients randomized to placebo (after stable esketamine response) relapsed within 16 weeks. Factors associated with higher relapse risk include shorter duration of response prior to discontinuation, more severe treatment resistance, absence of concurrent conventional antidepressant therapy, and history of rapid relapse following prior ketamine discontinuation (Papakostas et al., 2020).

Planned discontinuation should be gradual -- extending inter-infusion intervals over weeks to months -- rather than abrupt, to identify the minimum effective frequency before full cessation. Close monitoring during and after discontinuation (weekly symptom assessment for at least one month following the last infusion) is essential for early detection of relapse.

Long-Term Outcomes

Effectiveness Data

Long-term effectiveness data for ketamine maintenance are derived primarily from retrospective analyses and open-label follow-up studies. Cusin and colleagues (2017), in a retrospective analysis published in Journal of Clinical Psychiatry, described outcomes of repeated ketamine infusions in 14 treatment-resistant depression patients followed for up to two years. The majority maintained clinically meaningful improvement with ongoing infusions at individually optimized intervals, and no significant loss of efficacy (tachyphylaxis) was observed over the observation period.

Wilkinson and colleagues (2018) conducted a systematic review of ketamine for treatment-resistant depression that included available long-term follow-up data, reporting sustained response rates of approximately 40-60% among patients receiving maintenance treatment at 3-12 months. Notably, response rates during maintenance were generally lower than acute induction response rates, suggesting that some proportion of initial responders do not maintain benefit despite ongoing treatment.

Tachyphylaxis Considerations

The question of whether ketamine loses efficacy with repeated use (tachyphylaxis) is clinically critical. Anecdotal clinical experience is mixed, with some practitioners reporting maintained efficacy over years of treatment and others observing gradual response attenuation. Preclinical data suggest potential for NMDA receptor adaptation following chronic blockade, including compensatory upregulation of receptor expression and changes in subunit composition (Bhatt et al., 2017). However, these adaptations have been demonstrated primarily with continuous exposure paradigms rather than the intermittent dosing used clinically.

To date, published clinical data do not consistently demonstrate tachyphylaxis within observation periods of up to two years. Dose escalation -- while sometimes employed clinically when efficacy appears to wane -- has not been systematically studied and carries the risk of increased side effects without guaranteed efficacy benefit.

Integration with Other Treatments

Concurrent Antidepressant Therapy

Most maintenance ketamine protocols are administered in the context of concurrent conventional antidepressant therapy. The rationale is dual: conventional antidepressants may contribute to sustained response between ketamine infusions and provide a safety net if ketamine is discontinued. Mathew and colleagues (2010) demonstrated that initiating lithium following successful ketamine response did not prevent relapse better than placebo, suggesting that not all conventional agents effectively "consolidate" the ketamine response, published in Biological Psychiatry. Identifying which concurrent medications best sustain ketamine's effects represents an important research priority.

Psychotherapy Integration

The combination of maintenance ketamine with structured psychotherapy represents an underexplored but theoretically compelling approach. If ketamine's synaptic plasticity effects create windows of enhanced therapeutic learning, timing psychotherapy sessions during the period of peak neuroplastic enhancement (24-72 hours post-infusion) could consolidate psychological gains and potentially extend the durability of each infusion's benefit. This hypothesis, while supported by preclinical plasticity data, awaits clinical validation in maintenance treatment studies.

Monitoring During Long-Term Maintenance

Recommended Monitoring Schedule

Long-term maintenance protocols should incorporate systematic safety monitoring:

• Liver function tests: Every three to six months, given reports of ketamine-associated hepatotoxicity
• Urinalysis and bladder symptom assessment: Every three to six months, monitoring for lower urinary tract symptoms
• Cognitive screening: Every six to twelve months, using validated neuropsychological measures
• Substance use assessment: Ongoing, including screening for ketamine misuse or diversion
• Blood pressure monitoring: Each infusion session, with review of trends over time
• Depression severity rating: Each infusion session, using validated instruments (PHQ-9, MADRS, or QIDS-SR)

Treatment Response Documentation

Systematic documentation of treatment response -- including depression severity scores, functional status, and side effect burden at each treatment encounter -- is essential for optimizing maintenance protocols and supporting clinical decision-making. Trends in these measures guide decisions about interval adjustment, dose modification, and treatment discontinuation.

Conclusion

Ketamine maintenance infusion protocols represent an evolving clinical practice shaped by limited but growing evidence. The current approach -- multi-infusion induction followed by individually tailored maintenance at the longest effective inter-infusion interval -- balances efficacy against exposure-related safety concerns. Key unresolved questions include optimal maintenance frequency, total treatment duration, best concurrent medication strategies, and long-term safety. Randomized controlled trials comparing different maintenance schedules, investigating discontinuation timing, and evaluating combined pharmacotherapy-psychotherapy approaches are urgently needed to advance maintenance ketamine therapy from pragmatic clinical practice to evidence-based protocol.

References

• PubMed: Safety of Repeated Administration of Parenteral Ketamine for Depression — Safety data for repeated ketamine administration protocols in depression treatment
• PubMed: Long-Term Safety of Ketamine and Esketamine in Treatment of Depression — Review of long-term safety evidence for repeated ketamine and esketamine use
• FDA MedWatch: Safety Information and Adverse Event Reporting — FDA safety monitoring and adverse event reporting for ketamine treatments
• DailyMed: FDA Drug Label Information — National Library of Medicine database for official drug labeling and dosing guidance